Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glecaprevir/pibrentasvir prophylaxis in HCV-mismatched kidney transplant
NCT04575896Phase 4Completed
- Sponsor
- Johns Hopkins University
- Start
- Nov 2020
- Primary completion
- Nov 2023
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 4 trial of glecaprevir, pibrentasvir in hepatitis C (HCV), sponsored by Johns Hopkins University. Started Nov 2020; status: completed.
02
Drugs
glecaprevirpibrentasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT04575896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04575896.